Nucleic Acid Therapeutics CDMO Market Size, Trends, Analysis, and Outlook By Type (Gene Therapy, RNA-based Therapies), By Service (Process Development and Optimization, Manufacturing Services, Analytical and Quality Control Services, Others), By Application (Oncology, Genetic Disorders, Infectious Diseases, Others), By End-user (Pharmaceutical Companies, Government & Academic Research Institutes, Biotech Companies), by Region, Country, Segment, and Companies, 2024-2030
The global Nucleic Acid Therapeutics CDMO market size is poised to register 9.96% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Nucleic Acid Therapeutics CDMO market across By Type (Gene Therapy, RNA-based Therapies), By Service (Process Development and Optimization, Manufacturing Services, Analytical and Quality Control Services, Others), By Application (Oncology, Genetic Disorders, Infectious Diseases, Others), By End-user (Pharmaceutical Companies, Government & Academic Research Institutes, Biotech Companies).
The Nucleic Acid Therapeutics Contract Development and Manufacturing Organization (CDMO) market are witnessing robust growth driven by the increasing adoption of nucleic acid-based therapies for the treatment of various genetic and chronic diseases, along with the growing demand for outsourcing services to expedite drug development and manufacturing processes. Nucleic acid therapeutics, including antisense oligonucleotides, siRNAs, mRNA-based vaccines, and gene therapies, hold immense potential for addressing unmet medical needs and offering personalized treatment options. Key drivers of market growth include the rising investments in nucleic acid-based drug discovery and development, the advancements in delivery technologies for enhancing therapeutic efficacy and target specificity, and the expanding pipeline of nucleic acid therapeutics across diverse therapeutic areas. Additionally, the growing demand for specialized expertise and infrastructure for nucleic acid-based drug manufacturing, quality control, and regulatory compliance is driving the outsourcing trend among biopharmaceutical companies. Moreover, the increasing partnerships and collaborations between pharmaceutical firms and nucleic acid CDMOs, the surge in government funding for genomic medicine and precision therapeutics, and the rising focus on rare diseases and oncology indications are fueling market expansion. Furthermore, the emergence of novel RNA-based platforms, the adoption of single-use technologies for scalable production, and the implementation of stringent quality standards for ensuring product safety and efficacy are expected to drive market growth in the foreseeable future.
Nucleic Acid Therapeutics CDMO Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Nucleic Acid Therapeutics CDMO market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Nucleic Acid Therapeutics CDMO survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Nucleic Acid Therapeutics CDMO industry.
Key market trends defining the global Nucleic Acid Therapeutics CDMO demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Nucleic Acid Therapeutics CDMO Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Nucleic Acid Therapeutics CDMO industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Nucleic Acid Therapeutics CDMO companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Nucleic Acid Therapeutics CDMO industry
Leading Nucleic Acid Therapeutics CDMO companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Nucleic Acid Therapeutics CDMO companies.
Nucleic Acid Therapeutics CDMO Market Study- Strategic Analysis Review
The Nucleic Acid Therapeutics CDMO market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
The Nucleic Acid Therapeutics CDMO industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Nucleic Acid Therapeutics CDMO Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Nucleic Acid Therapeutics CDMO Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Nucleic Acid Therapeutics CDMO market segments. Similarly, Strong end-user demand is encouraging Canadian Nucleic Acid Therapeutics CDMO companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Nucleic Acid Therapeutics CDMO market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Nucleic Acid Therapeutics CDMO Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Nucleic Acid Therapeutics CDMO industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Nucleic Acid Therapeutics CDMO market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Nucleic Acid Therapeutics CDMO Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Nucleic Acid Therapeutics CDMO in Asia Pacific. In particular, China, India, and South East Asian Nucleic Acid Therapeutics CDMO markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Nucleic Acid Therapeutics CDMO Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Nucleic Acid Therapeutics CDMO Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Nucleic Acid Therapeutics CDMO market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Nucleic Acid Therapeutics CDMO.
Nucleic Acid Therapeutics CDMO Market Company Profiles
The global Nucleic Acid Therapeutics CDMO market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Catalent, Cognate BioServices, Danaher, Eurofins Genomics, FUJIFILM Diosynth Biotechnologies, Lonza, Oxford Biomedica, Sirion Biotech, Thermo Fisher Scientific
Recent Nucleic Acid Therapeutics CDMO Market Developments
The global Nucleic Acid Therapeutics CDMO market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Nucleic Acid Therapeutics CDMO Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
By Type
Gene Therapy
RNA-based Therapies
By Service
Process Development and Optimization
Manufacturing Services
Analytical and Quality Control Services
Others
By End-User
Pharmaceutical Companies
Government & Academic Research Institutes
Biotech Companies
By Application
Oncology
Genetic Disorders
Infectious Diseases
Others
Geographical Segmentation:
Catalent
Cognate BioServices
Danaher
Eurofins Genomics
FUJIFILM Diosynth Biotechnologies
Lonza
Oxford Biomedica
Sirion Biotech
Thermo Fisher Scientific
Formats Available: Excel, PDF, and PPT
The Nucleic Acid Therapeutics Contract Development and Manufacturing Organization (CDMO) market are witnessing robust growth driven by the increasing adoption of nucleic acid-based therapies for the treatment of various genetic and chronic diseases, along with the growing demand for outsourcing services to expedite drug development and manufacturing processes. Nucleic acid therapeutics, including antisense oligonucleotides, siRNAs, mRNA-based vaccines, and gene therapies, hold immense potential for addressing unmet medical needs and offering personalized treatment options. Key drivers of market growth include the rising investments in nucleic acid-based drug discovery and development, the advancements in delivery technologies for enhancing therapeutic efficacy and target specificity, and the expanding pipeline of nucleic acid therapeutics across diverse therapeutic areas. Additionally, the growing demand for specialized expertise and infrastructure for nucleic acid-based drug manufacturing, quality control, and regulatory compliance is driving the outsourcing trend among biopharmaceutical companies. Moreover, the increasing partnerships and collaborations between pharmaceutical firms and nucleic acid CDMOs, the surge in government funding for genomic medicine and precision therapeutics, and the rising focus on rare diseases and oncology indications are fueling market expansion. Furthermore, the emergence of novel RNA-based platforms, the adoption of single-use technologies for scalable production, and the implementation of stringent quality standards for ensuring product safety and efficacy are expected to drive market growth in the foreseeable future.
Nucleic Acid Therapeutics CDMO Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Nucleic Acid Therapeutics CDMO market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Nucleic Acid Therapeutics CDMO survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Nucleic Acid Therapeutics CDMO industry.
Key market trends defining the global Nucleic Acid Therapeutics CDMO demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Nucleic Acid Therapeutics CDMO Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Nucleic Acid Therapeutics CDMO industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Nucleic Acid Therapeutics CDMO companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Nucleic Acid Therapeutics CDMO industry
Leading Nucleic Acid Therapeutics CDMO companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Nucleic Acid Therapeutics CDMO companies.
Nucleic Acid Therapeutics CDMO Market Study- Strategic Analysis Review
The Nucleic Acid Therapeutics CDMO market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
- Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
- Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
- Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
- Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.
The Nucleic Acid Therapeutics CDMO industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Nucleic Acid Therapeutics CDMO Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Nucleic Acid Therapeutics CDMO Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Nucleic Acid Therapeutics CDMO market segments. Similarly, Strong end-user demand is encouraging Canadian Nucleic Acid Therapeutics CDMO companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Nucleic Acid Therapeutics CDMO market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Nucleic Acid Therapeutics CDMO Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Nucleic Acid Therapeutics CDMO industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Nucleic Acid Therapeutics CDMO market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Nucleic Acid Therapeutics CDMO Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Nucleic Acid Therapeutics CDMO in Asia Pacific. In particular, China, India, and South East Asian Nucleic Acid Therapeutics CDMO markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Nucleic Acid Therapeutics CDMO Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Nucleic Acid Therapeutics CDMO Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Nucleic Acid Therapeutics CDMO market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Nucleic Acid Therapeutics CDMO.
Nucleic Acid Therapeutics CDMO Market Company Profiles
The global Nucleic Acid Therapeutics CDMO market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Catalent, Cognate BioServices, Danaher, Eurofins Genomics, FUJIFILM Diosynth Biotechnologies, Lonza, Oxford Biomedica, Sirion Biotech, Thermo Fisher Scientific
Recent Nucleic Acid Therapeutics CDMO Market Developments
The global Nucleic Acid Therapeutics CDMO market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Nucleic Acid Therapeutics CDMO Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
- Pricing Analysis
- Value Chain Analysis
- SWOT Profile
- Market Dynamics- Trends, Drivers, Challenges
- Porter’s Five Forces Analysis
- Macroeconomic Impact Analysis
- Case Scenarios- Low, Base, High
By Type
Gene Therapy
RNA-based Therapies
By Service
Process Development and Optimization
Manufacturing Services
Analytical and Quality Control Services
Others
By End-User
Pharmaceutical Companies
Government & Academic Research Institutes
Biotech Companies
By Application
Oncology
Genetic Disorders
Infectious Diseases
Others
Geographical Segmentation:
- North America (3 markets)
- Europe (6 markets)
- Asia Pacific (6 markets)
- Latin America (3 markets)
- Middle East Africa (5 markets)
Catalent
Cognate BioServices
Danaher
Eurofins Genomics
FUJIFILM Diosynth Biotechnologies
Lonza
Oxford Biomedica
Sirion Biotech
Thermo Fisher Scientific
Formats Available: Excel, PDF, and PPT
1. EXECUTIVE SUMMARY
1.1 Nucleic Acid Therapeutics CDMO Market Overview and Key Findings, 2024
1.2 Nucleic Acid Therapeutics CDMO Market Size and Growth Outlook, 2021- 2030
1.3 Nucleic Acid Therapeutics CDMO Market Growth Opportunities to 2030
1.4 Key Nucleic Acid Therapeutics CDMO Market Trends and Challenges
1.4.1 Nucleic Acid Therapeutics CDMO Market Drivers and Trends
1.4.2 Nucleic Acid Therapeutics CDMO Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Nucleic Acid Therapeutics CDMO Companies
2. NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE OUTLOOK TO 2030
2.1 Nucleic Acid Therapeutics CDMO Market Size Outlook, USD Million, 2021- 2030
2.2 Nucleic Acid Therapeutics CDMO Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. NUCLEIC ACID THERAPEUTICS CDMO MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. NUCLEIC ACID THERAPEUTICS CDMO MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Type
Gene Therapy
RNA-based Therapies
By Service
Process Development and Optimization
Manufacturing Services
Analytical and Quality Control Services
Others
By End-User
Pharmaceutical Companies
Government & Academic Research Institutes
Biotech Companies
By Application
Oncology
Genetic Disorders
Infectious Diseases
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Nucleic Acid Therapeutics CDMO Market, 2025
5.2 Asia Pacific Nucleic Acid Therapeutics CDMO Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Nucleic Acid Therapeutics CDMO Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Nucleic Acid Therapeutics CDMO Market, 2025
5.5 Europe Nucleic Acid Therapeutics CDMO Market Size Outlook by Type, 2021- 2030
5.6 Europe Nucleic Acid Therapeutics CDMO Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Nucleic Acid Therapeutics CDMO Market, 2025
5.8 North America Nucleic Acid Therapeutics CDMO Market Size Outlook by Type, 2021- 2030
5.9 North America Nucleic Acid Therapeutics CDMO Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Nucleic Acid Therapeutics CDMO Market, 2025
5.11 South America Pacific Nucleic Acid Therapeutics CDMO Market Size Outlook by Type, 2021- 2030
5.12 South America Nucleic Acid Therapeutics CDMO Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Nucleic Acid Therapeutics CDMO Market, 2025
5.14 Middle East Africa Nucleic Acid Therapeutics CDMO Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Nucleic Acid Therapeutics CDMO Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Nucleic Acid Therapeutics CDMO Market Size Outlook and Revenue Growth Forecasts
6.2 US Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
7. NUCLEIC ACID THERAPEUTICS CDMO MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. NUCLEIC ACID THERAPEUTICS CDMO COMPANY PROFILES
8.1 Profiles of Leading Nucleic Acid Therapeutics CDMO Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Catalent
Cognate BioServices
Danaher
Eurofins Genomics
FUJIFILM Diosynth Biotechnologies
Lonza
Oxford Biomedica
Sirion Biotech
Thermo Fisher Scientific
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
1.1 Nucleic Acid Therapeutics CDMO Market Overview and Key Findings, 2024
1.2 Nucleic Acid Therapeutics CDMO Market Size and Growth Outlook, 2021- 2030
1.3 Nucleic Acid Therapeutics CDMO Market Growth Opportunities to 2030
1.4 Key Nucleic Acid Therapeutics CDMO Market Trends and Challenges
1.4.1 Nucleic Acid Therapeutics CDMO Market Drivers and Trends
1.4.2 Nucleic Acid Therapeutics CDMO Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Nucleic Acid Therapeutics CDMO Companies
2. NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE OUTLOOK TO 2030
2.1 Nucleic Acid Therapeutics CDMO Market Size Outlook, USD Million, 2021- 2030
2.2 Nucleic Acid Therapeutics CDMO Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. NUCLEIC ACID THERAPEUTICS CDMO MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. NUCLEIC ACID THERAPEUTICS CDMO MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Type
Gene Therapy
RNA-based Therapies
By Service
Process Development and Optimization
Manufacturing Services
Analytical and Quality Control Services
Others
By End-User
Pharmaceutical Companies
Government & Academic Research Institutes
Biotech Companies
By Application
Oncology
Genetic Disorders
Infectious Diseases
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Nucleic Acid Therapeutics CDMO Market, 2025
5.2 Asia Pacific Nucleic Acid Therapeutics CDMO Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Nucleic Acid Therapeutics CDMO Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Nucleic Acid Therapeutics CDMO Market, 2025
5.5 Europe Nucleic Acid Therapeutics CDMO Market Size Outlook by Type, 2021- 2030
5.6 Europe Nucleic Acid Therapeutics CDMO Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Nucleic Acid Therapeutics CDMO Market, 2025
5.8 North America Nucleic Acid Therapeutics CDMO Market Size Outlook by Type, 2021- 2030
5.9 North America Nucleic Acid Therapeutics CDMO Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Nucleic Acid Therapeutics CDMO Market, 2025
5.11 South America Pacific Nucleic Acid Therapeutics CDMO Market Size Outlook by Type, 2021- 2030
5.12 South America Nucleic Acid Therapeutics CDMO Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Nucleic Acid Therapeutics CDMO Market, 2025
5.14 Middle East Africa Nucleic Acid Therapeutics CDMO Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Nucleic Acid Therapeutics CDMO Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Nucleic Acid Therapeutics CDMO Market Size Outlook and Revenue Growth Forecasts
6.2 US Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Nucleic Acid Therapeutics CDMO Industry Drivers and Opportunities
7. NUCLEIC ACID THERAPEUTICS CDMO MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. NUCLEIC ACID THERAPEUTICS CDMO COMPANY PROFILES
8.1 Profiles of Leading Nucleic Acid Therapeutics CDMO Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Catalent
Cognate BioServices
Danaher
Eurofins Genomics
FUJIFILM Diosynth Biotechnologies
Lonza
Oxford Biomedica
Sirion Biotech
Thermo Fisher Scientific
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
